Anti-Rheumatic Drugs - Southeast Asia

In Southeast Asia, the revenue in the Anti-Rheumatic Drugs market is forecasted to reach US$312.50m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.46%, leading to a market volume of US$335.90m by 2029.
When compared globally, United States is projected to generate the highest revenue in the Anti-Rheumatic Drugs market, with US$34.70bn in 2024.
In Southeast Asia, the demand for anti-rheumatic drugs is on the rise as the region faces an increasing prevalence of rheumatic diseases.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The demand for Anti-Rheumatic Drugs in Southeast Asia has been on the rise in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis and other related conditions are the primary customers for Anti-Rheumatic Drugs. The preference for these drugs is due to their effectiveness in reducing inflammation and relieving pain associated with these conditions. Patients also prefer these drugs due to their ease of use and low side-effects.

Trends in the market: Indonesia and Thailand are the largest markets for Anti-Rheumatic Drugs in Southeast Asia. The trend in these countries is towards the use of biologic drugs, which offer greater efficacy and fewer side-effects. However, the high cost of these drugs is a major challenge for patients, and there is a growing demand for more affordable alternatives. In Vietnam and the Philippines, the market for Anti-Rheumatic Drugs is dominated by non-steroidal anti-inflammatory drugs (NSAIDs), which are cheaper and more widely available. However, there is a growing trend towards the use of disease-modifying anti-rheumatic drugs (DMARDs) in these countries.

Local special circumstances: In Indonesia, the government has implemented a national health insurance scheme, which has increased access to Anti-Rheumatic Drugs for patients. However, there are still significant regional disparities in access to healthcare, with patients in rural areas having limited access to these drugs. In Thailand, the government has implemented price controls on biologic drugs, which has made them more affordable for patients. However, there is still a significant out-of-pocket cost for patients, which limits access to these drugs.

Underlying macroeconomic factors: The growing middle class in Southeast Asia has led to an increase in the prevalence of rheumatoid arthritis and other related conditions. This has driven demand for Anti-Rheumatic Drugs in the region. However, the high cost of these drugs is a major challenge for patients, particularly in countries with limited access to healthcare. The increasing availability of generic drugs is expected to drive down the cost of Anti-Rheumatic Drugs in the region, which will increase access for patients. Additionally, the increasing prevalence of rheumatoid arthritis and related conditions is expected to continue to drive demand for these drugs in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.